ADAP News and Press, Adaptimmune Therapeutics plc From 03/06/23

BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed engineered TCR T-cell therapy for a solid tumor 52% (13/25) response rate in ovarian, bladder and head & neck cancers in the Phase 1 SURPASS trial with next-generati...

2023-03-06 06:27:26 ET Adaptimmune Therapeutics ( NASDAQ: ADAP ) and TCR² Therapeutics ( NASDAQ: TCRR ) have entered into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a preeminent cell therapy...

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transac...

Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q4 earnings results on Monday, March 6th, before market open. The consensus EPS Estimate is -$0.25 and the consensus Revenue Estimate is $5.08M (+262.9% Y/Y). Over the last 1 year, ADAP has beaten EPS estimates 75% of t...

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and full year ended December ...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel - - Based on these results, the Company initiated a Phase 2 trial with afami-cel for people with sarcoma, SPEARHEAD-1, and these data are being used to support a rolling BLA submi...

Adaptimmune Therapeutics ( NASDAQ: ADAP ) stock rose ~17% on Tuesday after Guggenheim upgraded the U.K.-based company's stock to Buy from Neutral. The SA Quant Rating on the shares is Buy , which takes into account factors such as Momentum, Profitability, and Valuation am...

- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial sarcoma has a high unmet medical need and the pivotal trial met its primary endpoint with an overall response rate of ~39% after a single dose of afami-cel - - Adaptimmune plans t...

Summary ADAP has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline. I will continue watching the stock with interest. Just not going to buy now. Adaptimmune ( ADAP ), I noted previously, had been a ...